Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

The $250 (yep, there’s no missing ‘M’ from the end of that number) Apple was awarded in its patent infringement case against Masimo might seem amusing – as John Gruber wryly noted ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

Apple is fighting a running legal battle with the health tech company Masimo over pulse oximetry technology and smartwatch design patents. A jury in a federal trial awarded Apple a paltry $250 ...

The FDA has only approved one medical wearable that provides continuous oxygen saturation (SpO2) and pulse rate tracking: the Masimo W1 Medical watch. “If you really want a wearable that’s ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum ...